Summit Therapeutics Inc. — Director's Dealing 2022

Nov 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2022-11-15

Reporting Person: Cesano Alessandra (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-15	Stock Option (right to buy)	$1.09	A	200000	Acquired	2032-11-15	Common Stock (200000.0)	Direct
2022-11-15	Stock Option (right to buy)	$1.09	A	4166	Acquired	2032-11-15	Common Stock (4166.0)	Direct

Footnotes

F1: The option was granted on November 15, 2022. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 15, 2023.

F2: Not applicable.

F3: The option was granted on November 15, 2022 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days the Reporting Person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2022.